An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

✍ Scribed by Ravi Vij; David S. Siegel; Sundar Jagannath; Andrzej J. Jakubowiak; Alexander Keith Stewart; Kevin McDonagh; Nizar Bahlis; Andrew Belch; Lori A. Kunkel; Sandra Wear; Alvin F. Wong; Michael Wang

• Book ID: 117946813
• Publisher: John Wiley and Sons
• Year: 2012
• Tongue: English
• Weight: 198 KB
• Volume: 158
• Category: Article
• ISSN: 0007-1048
• DOI: 10.1111/j.1365-2141.2012.09232.x